Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.

Orbit Discovery

Orbit Discovery is a peptide drug discovery company spun out from the University of Oxford. The Company has developed a proprietary peptide synthesis and functional screening platform that promises to find new peptide drugs for difficult targets.

This technology allows Orbit to address high-value targets like G-protein coupled receptors (GPCRs) and T-cell receptors (TCRs) with a growing library of over 1 billion natural and non-natural peptides. Orbit is commercialising the platform by performing early stage lead-discovery for pharmaceutical and biopharmaceutical drug development programmes.


Professors Terry Rabbitts & Graham Ogg

Terry carried out his PhD at the MRC National Institute for Medical Research, Mill Hill and moved to the MRC Laboratory of Molecular Biology, Cambridge where he worked from 1973-2006.

At LMB, he succeeded Fred Sanger as joint Head of the Division of Protein and Nucleic Acid Chemistry with César Milstein. He was Director of the Leeds Institute of Molecular Medicine from 2007 to 2012 and was Professor of Molecular Biology at the Weatherall Institute of Molecular Medicine. Terry is currently Professor of Molecular Immunology at the Institute of Cancer Research, London.

Graham trained in medicine at University of Oxford before specialising in dermatology. Currently he is an MRC Programme Leader at the MRC Human Immunology Unit at the Weatherall Institute of Molecular Medicine (University of Oxford) and consultant dermatologist at the Oxford University NHS Trust.

Partner with us?

Get in touch